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The discovery of the severe combined immune deficient (SCID)
mouse by Bosma and co-workers (Bosma et al, 1983) opened up
avenues that allowed researchers to exploit this strain of mouse for
the xenografting of human tumours and normal tissues in ways that
had not previously been possible. The SCID mouse proved of partic-
ular value to workers interested in the leukaemias and in
haematopoiesis, allowing for early engraftment experiments initially
with cell lines (Kamel-Reid et al, 1989) and later with primary
haematological malignant (Cesano et al, 1991; Kamel-Reid et al,
1991) and non-malignant cells (Lapidot et al, 1992; Kollmann et al,
1994). The relative ease with which SCID mice accept xenografts
can be attributed to their virtual total lack of functional B- and T-
cells. This is due to a defect in their recombinase system that
prevents immunoglobulin and T-cell receptor (TCR) gene rearr-
angements that would normally drive the diversity of the antigen
recognition repertoire in normal mice (Kotloff et al, 1993).
Subsequently progenitor B- and T-cells fail to develop to a fully
functional mature state in SCID mice (Custer et al, 1985) and
instead undergo apoptosis early in their life history. SCID mice do
however possess a virtually fully functional non-adaptive immune
system with normal levels of tissue macrophages, NK cells, serum
complement activity and normal myelopoiesis (Dorshkind et al,
1984, 1985). The presence of functional NK cells and tissue
macrophages has in some instances created a barrier to successful
engraftment with both normal and malignant primary haematolog-
ical material. This problem has been at least partially overcome in
the past by depleting SCID mice of their NK cells by treatment
prior to xenografting with non-lethal doses of total body radiation,
anti-asialo GM1 antibody (Shpitz et al, 1994) or cytotoxic drugs
such as cyclophosphamide. NK cells are however only transiently
eliminated by such methods and this makes the SCID mouse of
limited value in long-term engraftment studies where the reappear-
ance of NK cells might likely compromise the biological
behaviour of the graft. 
Non-Obese Diabetic mice (NOD/Lt strain) have a significant
deficit in their non-adaptive immunity with reductions in NK cell
functionality (Kataoka et al, 1983; Serreze and Leiter, 1988), an
absence of circulating complement components (Baxter and Cooke,
1993) and functional defects in antigen presenting cells (APC)
(Serreze et al, 1993). NOD/Lt mice develop a high incidence
of autoimmune (type 1) insulin-dependent diabetes mellitus
(IDDM) mediated by auto reactive T-cells (Christianson et al,
1993). This led Shultz and co-workers (Shultz et al, 1995)
to backcross the scid mutation onto the NOD/Lt strain back-
ground, resulting in an immunodeficient mouse (NOD/LtSz-
scid/scid) with multiple defects in adaptive as well as non-adaptive
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Summary Groups of 8 to ten SCID (CB.17 scid/scid) or NOD/SCID (NOD/LtSz-scid/scid) mice were injected i.v. with two million human HSB-
2 T-ALL cells on day 1 (SCID-HSB-2 and NOD/SCID-HSB-2 mice) and treated later with 3 i.v. 10 µ g doses of the anti-CD7 antibody HB2 on
days 7, 9 and 11 or with a single 10 µ g dose of HB2-SAPORIN or a 7.4 µ g dose of HB2-F(ab)2-SAPORIN immunotoxin (IT) on day 7.
Treatment of SCID-HSB-2 mice with HB2-SAPORIN led to a significant prolongation in the time to development of signs and symptoms of
disease compared with PBS sham-treated controls with 80% of animals surviving disease-free. In contrast treatment with HB2-F(ab)2-
SAPORIN was significantly less effective in SCID-HSB-2 mice with 80% of animals in this treatment group developing leukaemia over the
course of the study. HB2 antibody treatment of SCID-HSB-2 mice also led to a significant prolongation in time to leukaemia development
compared with sham-treated controls with 37% of animals in this treatment group disease-free at termination of the study. In contrast HB2
antibody treatment of NOD/SCID-HSB-2 mice had no therapeutic effect in these animals and the therapeutic effectiveness of both HB2-
SAPORIN and HB2-F(ab)2-SAPORIN ITs was similar and significantly reduced compared to the effect observed in SCID-HSB-2 mice. It was
initially thought that the lack of therapeutic effect of antibody and IT in NOD-SCID-HSB-2 mice might relate to their putative lack of NK cells but
flow cytometric and functional studies with NOD-SCID mouse splenocytes revealed that these animals do have some functional NK cells
though fewer in number and possibly lower in functionality than those of SCID mice. We reason that the complete lack of therapeutic effect of
HB2 antibody and the reduced effect of HB2-SAPORIN in NOD/SCID mice is due to the reduced cytolytic activity of NOD/SCID NK cells which
is probably below a certain critical threshold value in these animals. We conclude from this that immunotherapeutics like HB2-SAPORIN would
be more accurately assessed for intrinsic potency in NOD/SCID mice where the effects of NK cell and possibly other non-adaptive immune
mechanisms would not have a significant influence. © 2000 Cancer Research Campaign http://www.bjcancer.com
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NOD/SCID mice. Moreover, the profound B- and T-cell defi-
ciency acquired through the scid mutation means that NOD/SCID
mice do not develop IDDM but they do have a high incidence for
developing spontaneous thymomas (Prochazka et al, 1992) giving
them a life expectancy of 12 months or less. The profound immun-
odeficient state of NOD/SCID mice has resulted in better and
more robust engraftment levels with normal and malignant haema-
tological material (Wang et al, 1995) that has allowed for a quanti-
tative evaluation of leukaemic stem cell populations in primary
patient derived samples (Dick, 1996) and the establishment of
intact human haematopoietic systems (Bhatia et al, 1997). 
SCID mice have in the past provided a useful tool for the
preclinical evaluation of novel antibody-based therapies for
human acute leukaemias and lymphomas. Nearly all of these
previous studies have been based upon cell line models, which
may not accurately recapitulate the disease process and behaviour
in humans (Flavell, 1996). A major advance in this area would be
to develop the capability of engrafting a sufficiently large enough
cohort of animals with human leukaemia cells from one indi-
vidual patient in order to undertake therapy studies with sufficient
statistical power. In this context several workers have recently
reported the several-fold expansion of human T-cell leukaemia
(Yu et al, 1999) and myeloma cells (Pilarski et al, 2000) in
preconditioned NOD/SCID. As a preliminary undertaking to
progressing the idea of developing in vivo therapy models for
individual patients for the preclinical evaluation of antibody-
based therapeutics we wanted to ensure that such therapy studies
were feasible in NOD/SCID mice utilizing an existing cell line
model of human T-ALL, which has been well defined in the SCID
mouse. Our strategy has been to compare the therapeutic efficacy
of the murine anti-CD7 IgG1 antibody HB2 and the immunotoxin
HB2-SAPORIN in SCID and NOD/SCID mice engrafted with the
human CD7+ T-ALL cell line HSB-2. We clearly demonstrate that
the therapeutic effectiveness of HB2 antibody is significant in
SCID mice but is non-existent in NOD/SCID mice and also show
that HB2-SAPORIN IT treatment is significantly reduced in
NOD/SCID when compared with the outcome obtained in SCID
mice. These current experimental findings taken together with our
previous observations (Flavell et al, 1998) lead us to propose that
the NOD/SCID mouse model of HSB-2 human leukaemia more
accurately reflects the intrinsic in vivo therapeutic effectiveness
of HB2-SAPORIN treatment which unlike the SCID mouse
model is not influenced by the presence of NK cells which we
have previously shown can have significant effects on the in vivo
therapeutic potency of IT treatment. 
MATERIALS AND METHODS 
SCID and NOD/SCID mice 
Pathogen free CB.17 scid/scid (SCID) mice of both sexes were
produced from our own breeding colony. NOD/LtSz-scid/scid
mice (NOD/SCID) were also provided from our own breeding
colony with breeding pairs kindly supplied by Dr Finbarr Cotter
(Institute of Child Health, London, UK). All animals were main-
tained in filter top micro isolator cages and provided with sterile
water and food ad libitum under conditions complying with British
Government Home Office regulations. All manipulations of experi-
mental animals were conducted in a laminar flow hood using
strictly controlled procedures adhering to the UKCCCG Guidelines
for the Welfare of Animals in Experimental Neoplasia to minimize
stress or suffering (Workman et al, 1998). 
HSB-2 human T-ALL cell line and YAC-1 murine
lymphoma cell line 
The CD7+ human cell line HSB-2 (Adams et al, 1970) and the
murine lymphoma cell line YAC-1 (Cikes et al, 1973) were main-
tained in the logarithmic phase of growth in RPMI 1640 medium
containing 10% fetal calf serum and supplements of 2 mM of
sodium pyruvate and glutamine (R10 medium) at 37˚C under a
humidified atmosphere of 5% CO2. 
Antibodies 
The rat anti-mouse antibodies AT37 (anti-CD2), 6D5 (anti-CD19)
and F4/80 (anti-macrophage) and the mouse anti-mouse NK cell
antibody NK1-1 directly conjugated to phycoerythrin were obtained
from Serotec Ltd (Kidlington, UK). The rat antibody 2.4G2 directed
against mouse Fcγ RII/III (anti-CD16/32) was obtained from
PharMingen (San Diego, CA). The murine hybridoma cell line HB2
producing an IgG1 antibody directed against the human CD7 mole-
cule was obtained from the American Tissue Culture Collection
(Bethesda, MD). Bulk HB2 antibody was produced in vitro from
this hybridoma on a Cellex Accusyst R hollow fibre bioreactor
system (Cellex, Minneapolis, MN, USA). F(ab )2 fragments of
HB2 antibody were produced by pepsin digestion of native HB2
antibody employing an ImmunoPure F(ab )2 kit from Pierce,
(Rockford, IL, USA) following the manufacturers instructions.
F(ab )2 HB2 antibody produced in this way gave a single band of
110 kD molecular weight on SDS-PAGE analysis under non-
reducing conditions and was wholly free of detectable contami-
nating Fc. 
Immunotoxin construction 
The immunotoxins HB2-SAPORIN and HB2-F(ab )2-SAPORIN
were constructed by conjugating molar equivalent amounts of HB2
antibody or its F(ab )2 fragment to saporin using the heterobifunc-
tional cross linking reagent N-succinimidyl 3-(2-pyridyldithio)propi-
onate (SPDP) as described previously (Thorpe et al, 1985). Only IT
containing 2 saporin moieties per IT molecule were used in these
studies because of their well defined characteristics and potency
as described by us previously (Flavell et al, 1997). The purity of
immunotoxins was confirmed by SDS-PAGE and were then dial-
ysed into PBS pH7.2, sterilized by passage through a 0.2 µ m filter
and stored deep frozen in 100 µ g aliquots at  80˚C. 
Chromium release assay 
Details of chromium release assays used to determine the lytic
capability of SCID and NOD/SCID splenocytes for HSB-2 and
YAC-1 cells both constitutively and as effectors in antibody-
dependent cellular cytotoxicity (ADCC) have been fully described
previously (Flavell et al, 1998). 
Flow cytometry 
Expression of the various antigen markers on SCID and NOD/
SCID splenocytes was determined on a Coulter Epics XL flow
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with the appropriate antibody as described (Flavell et al, 1998). 
In vivo experiments 
On day one of study, groups of 10 SCID or NOD/SCID mice were
injected into the tail vein with two million HSB-2 cells in a 200 µ l
volume of R10 medium (termed SCID-HSB-2 or NOD/SCID-HSB-
2 animals). We have described the growth and dissemination of the
human T-ALL cell line HSB-2 in SCID mice in detail previously
(Morland et al, 1994). We have observed that the pattern of disease
development and progression is virtually identical in NOD/SCID
mice (unpublished observations). The appropriate groups of SCID-
HSB-2 or NOD/SCID-HSB-2 mice were treated i.v. with three 10
µ g doses of HB2 antibody given on days 7, 9 and 11 or sham treated
with three doses of PBS given at the same time points. Other groups
of SCID-HSB-2 or NOD/SCID-HSB-2 animals received a single 10
µ g i.v. dose of HB2-SAPORIN or with a molar equivalent amount
(7.4 µ g) of HB2-F(ab)2-SAPORIN on day 7 or were sham treated
with a single i.v. injection of 200 µ l PBS on day 7. All animals were
monitored twice daily for the duration of the study and strictly
defined endpoints were enforced as per recommendations under the
UKCCCR guidelines (Workman et al, 1998) to ensure that no
animal suffered undue or unnecessary stress or pain during the
course of the study. Thus, animals showing any identifiable early
signs of being unwell were killed humanely and full post-mortem
examinations conducted to confirm the presence of tumour. 
Statistical analysis 
Log-Rank analysis (Peto’s method) using the SOLO statistics soft-
ware package (BMDP Statistical Software. Los Angeles, CA,
USA) was used to determine if there were any significant differ-
ences between the various therapy groups. P values of 0.05 or less
were considered as statistically significant in these studies. 
RESULTS 
Immunophenotypic analysis of SCID and NOD/SCID
splenocyte populations 
Comparative immunophenotypic analysis of splenocytes taken
from SCID and NOD/SCID mice was undertaken by single colour
flow cytometry and revealed the differences shown in Table 1.
32% of the splenic population of SCID mice were positive for the
NK cell marker NK1.1 compared with only 20% of NOD/SCID
splenocytes. Similarly there were fewer NOD/SCID splenocytes
expressing FcgRII/RIII compared with SCID splenocytes (22%
versus 37%, respectively) and also fewer macrophages identified
by the F4/80 antibody in NOD/SCID spleens compared with SCID
spleens (12% versus 17%). There were also marginally fewer CD2
expressing splenocytes in NOD/SCID mice but similar numbers of
CD19 expressing cells. 
Functional characteristics of SCID and NOD/SCID
splenocytes 
Constitutive cytotoxicity for YAC-1 and HSB-2 cells 
Splenocytes taken from SCID and NOD/SCID mice that had been
treated 24 h previously with 100 µ g poly IC i.v. were tested for
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Table 1 Immunophenotypic composition of splenocytes from CB.17 SCID
and NOD/SCID mice as determined by flow cytometry 
Surface
% positive splenocytes 
antigen SCID NOD/SCID 
NK 1.1 32 20 
F4/80 17 12 
CD16/32 37 22 
CD2 5 2 
CD19 2 2 
Figure 1 Lysis of (A) target YAC-1 cells or (B) HSB-2 cells expressed as a
percentage of 51Cr release following incubation with either CB.17 SCID (  ) or
NOD/SCID (  ) effector splenocytes at target:effector ratios ranging from
1:200 to 1:20. Bars, SD their ability to lyse target YAC-1 or HSB-2 cells in a chromium
release assay at target to effector (T:E) ratios ranging from 1:200
to 1:20. Figure 1A shows that at T:E ratios of 1:200 and 1:100
SCID and NOD/SCID splenocytes performed comparably, elic-
iting a similar degree of lysis of YAC-1 cells. However, at T:E
ratios of 1:50 and 1:20 NOD/SCID splenocytes declined in their
ability to lyse YAC-1 cells while SCID splenocytes maintained
their capacity at a level similar to that seen at the higher T:E ratios.
Neither SCID or NOD/SCID splenocytes were capable of lysing
HSB-2 cells at any of the T:E ratios studied (Figure 1B). 
Antibody-dependent cellular cytotoxicity (ADCC) 
Both SCID and NOD/SCID splenocytes were tested for their
ability to lyse target HSB-2 cells in an antibody-dependent cellular
cytotoxicity (ADCC) assay at a T:E ratio of 1:100 in the presence
of increasing concentrations of the anti-CD7 antibody HB2. The
results of this study are shown in Figure 2. The greatest degree of
target cell lysis was achieved with SCID mouse splenocytes at the
two highest antibody concentrations of 660 and 66 pM being 55%
and 52%, respectively compared with 31% and 37% lysis obtained
with NOD/SCID splenocytes at these same antibody concentra-
tions. In the same assay the irrelevant isotype matched control
antibody BU-12 (anti-CD19) used at the two highest concentra-
tions did not cause lysis of HSB-2 cells when either SCID or
NOD/SCID splenocytes were employed. 
Therapeutic effects of murine anti-CD7 antibody
treatment in SCID-HSB-2 and NOD/SCID-HSB-2 mice 
SCID mice injected i.v with two million HSB-2 cells on day 1 and
treated with three 10 µ g i.v. doses of HB2 antibody on days 7, 9 and
11 showed a significant (P = 0.0135) prolongation in the time taken
to develop symptoms compared with PBS sham-treated SCID mice,
with 37% of these animals alive and disease-free at elective termina-
tion of the experiment at 135 days (Figure 3A). In contrast HB2
antibody showed no significant therapeutic effect (P = 0.243) in
identically treated NOD/SCID mice, with antibody-treated animals
developing symptoms at virtually the same rate as PBS sham-treated
NOD/SCID control animals and with all animals in the antibody-
treated group dead by 102 days (Figure 3A). In this instance
NOD/SCID PBS sham-treated controls succumbed to disease at a
slightly faster rate overall than the equivalent SCID control animals,
though the difference between them was not significant (Figure 3A). 
Therapeutic effects of HB2-SAPORIN and HB2-F(ab)2-
SAPORIN in SCID-HSB-2 and NOD/SCID-
HSB-2 mice 
To determine the therapeutic effect of the anti-CD7 HB2-SAPORIN
IT in SCID-HSB-2 and NOD/SCID-HSB-2 mice we injected a
single 10 µ g i.v. dose of HB2-SAPORIN IT into mice 7 days after
i.v. challenge with two million HSB-2 cells. The IT had a highly
significant therapeutic effect (P = 0.0002) in SCID-HSB-2 mice
compared with PBS sham-treated SCID control animals, with 80%
of the IT treated animals alive and disease-free for the 135 day dura-
tion of the experiment (Figure 3B). In identically treated NOD/SCID
mice the IT was therapeutically ineffective in the majority of
animals, with 70% of these animals developing signs and symptoms
of leukaemia growth at the same rate as the PBS sham-treated
control animals (Figure 3B) but with an eventual 30% of animals
disease-free at elective termination of the experiment. However,
despite this 30% survival rate in the IT-treated NOD/SCID group
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Figure 2 Lysis of target HSB-2 cells by ADCC elicited by SCID (  ) or
NOD/SCID mouse (  ) effector splenocytes at a 100:1 E:T ratio in the
presence of increasing concentrations of the anti-CD7 antibody HB2. Lysis of
target HSB-2 cells in the presence of the irrelevant anti-CD19 isotype
matched control antibody BU-12 with CB.17 SCID (   ) or NOD/SCID (   )
splenocytes is also shown. Bars, SD 
Figure 3 Kaplan-Meyer plots for groups of SCID (closed symbols) or
NOD/SCID mice (open symbols) injected i.v. on day 1 with two million HSB-2
cells and treated with (A) three 10 µ g i.v. injections of HB2 antibody given on
days 7, 9 and 11 (  ,    ) or sham treated at the same times with 200 µ l of PBS
(  ,    ) or (B) treated with a single 10 µ g i.v. injection of HB2-SAPORIN on day
7 (  ,    ) or sham treated at the same time with 200 µ l PBS (  ,    )(compared with a zero survival rate in the NOD/SCID controls) the
therapeutic effect was not found to be significant by log-rank
analysis (P = 0.296). This was probably because the rapid rate at
which the majority of animals developed disease early in the experi-
ment skewed the statistical test. In this particular instance SCID and
NOD/SCID PBS sham-treated animals died at a very similar rate and
thus there was no significant difference between them. 
We also conducted an experiment to compare the therapeutic
effects of HB2-SAPORIN and HB2-F(ab)2-SAPORIN immuno-
toxins in SCID-HSB-2 and NOD/SCID-HSB-2 mice and the
results we obtained are shown in Figure 4. In SCID-HSB-2 mice
the HB2-F(ab)2-SAPORIN IT performed significantly less well
therapeutically than the HB2-SAPORIN IT constructed with intact
HB2 antibody (Figure 4A). In this instance the HB2-F(ab)2-
SAPORIN-treated animals developed signs and symptoms of
leukaemia at a more rapid rate than animals treated with HB2-
SAPORIN and moreover only 20% of these animals were alive
and leukaemia-free upon elective termination of the experiment at
170 days, in contrast to the 43% of animals treated with HB2-
SAPORIN IT. Figure 3B shows that there was no significant
difference in the therapeutic performance of either IT in
NOD/SCID-HSB-2 mice. In this instance both HB2-SAPORIN
and HB2-F(ab)2-SAPORIN were almost completely ineffective,
with animals from both IT therapy groups developing signs and
symptoms of leukaemia only at a slightly slower rate than the PBS
control group. There was one single animal from within the HB2-
F(ab)2-SAPORIN treatment group that only developed signs and
symptoms of HSB-2 leukaemia growth after 151 days, otherwise
all other animals developed disease at a similar rate to HB2-
SAPORIN-treated animals. The differences between the HB2-
SAPORIN and HB2-F(ab)2-SAPORIN-treated animals and PBS
sham-treated controls were not significant. Therefore in this partic-
ular experiment the lack of therapeutic effect of HB2-SAPORIN IT
in NOD/SCID-HSB-2 mice was even more pronounced than in the
previously described experiment illustrated in Figure 2B. 
DISCUSSION 
The two major findings to emerge from this study are (a) that the
therapy of NOD/SCID mice bearing the human CD7+ T-cell acute
leukaemia cell line HSB-2 with the murine IgG1 antibody HB2
directed against the human CD7 molecule is therapeutically totally
ineffective in contrast to the significant therapeutic effect that is
achieved with this antibody in SCID mice and (b) that the thera-
peutic effectiveness of the anti-CD7 IT HB2-SAPORIN is signifi-
cantly reduced in NOD/SCID-HSB-2 mice compared with that
obtained in SCID-HSB-2 mice. The in vivo experiments showing
this, have been repeated on three separate occasions with similar
results each time and two of these have been reported here. On each
occasion the therapeutic effect of HB2 antibody or HB2-SAPORIN
IT has been found to be significantly reduced in NOD/SCID-HSB-2
mice compared with SCID-HSB-2 mice. In one experiment reported
here there was virtually no observable therapeutic effect of HB2-
SAPORIN in NOD/SCID-HSB-2 mice (see Figure 4B) and in the
other two studies, one of which is reported here (see Figure 3B),
there was a therapeutic effect in a proportion of the NOD/SCID-
HSB-2 mice but overall this effect was significantly reduced. We
have previously shown that the antibody-mediated anti-leukaemia
effect that is exerted by HB2 antibody in SCID-HSB-2 mice is very
likely mediated by SCID mouse NK cells (Flavell et al, 1998) which
we and others have shown to be functionally present in SCID mice
(Dorshkind et al, 1985; Flavell et al, 1998). We were also able to
show in the present study that NOD/SCID mice possess functionally
intact NK cell-like activities that were capable of lysing target YAC-
1 cells and of also participating in ADCC against antibody coated
target HSB-2 cells. However, it would appear that there are fewer
Fcγ RII/RIII and NK1.1+ NK cells present in the spleens of
NOD/SCID mice. Furthermore our study also suggests that
NOD/SCID NK cells are probably functionally less active than the
equivalent SCID mouse cell counterparts. Thus we were able to
demonstrate in the present study a diminishing lytic capability of
NOD/SCID mouse splenocytes for YAC-1 target cells at lower T:E
ratios that was not paralleled by SCID splenocytes when used at the
same ratios and furthermore a reduced lytic capacity of NOD/SCID
splenocytes against HSB-2 cells in an ADCC assay compared with
that seen with SCID splenocytes. Despite this, it is quite surprising
that splenocytes from NOD/SCID mice, which do appear to possess
some in vitro lytic NK cell-like activities, albeit at reduced levels,
fail to elicit an effective in vivo ADCC anti-leukaemia response with
HB2 antibody. One possibility is that this is because the functional
quality of the relevant NOD/SCID splenocyte population is below
the threshold value to be effective in vivo. An alternative explana-
tion might be that the extra-splenic tissue distribution of functional
NK cells is sparse in NOD/SCID mice and/or that the migration of
Immunotherapy in immunodeprived mice 1759
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Figure 4 Kaplan-Meyer plots for groups of (A) SCID mice and (B)
NOD/SCID mice treated with a single i.v. injection of 10 µ g HB2-SAPORIN IT
(  ), 7.4 µ g HB2-F(ab)2-SAPORIN (  ) or sham treated at the same time with
200 µ l PBS (  )NK cells into tissues is in some way impaired in these animals. The
latter would prevent NK cells coming into direct contact with HSB-
2 cells in extra-splenic tissue locations and thus prevent the engage-
ment of NK cell surface Fcγ RIII with the Fc domain of antibody
coating the target leukaemia cell, a step that is an absolute require-
ment for cellular cytotoxicity. This study has not attempted to
examine the distribution of NK1.1 cells in other NOD/SCID tissues
other than spleen and it is therefore not possible to draw any firm
conclusions regarding these various possibilities at this stage,
though it is the opinion of the authors that it is the impairment in
NOD/SCID NK cell lytic function that more likely accounts for the
apparent lack of in vivo directed ADCC against HSB-2 cells. 
We also demonstrated in the present study that the anti-CD7 IT
HB2-SAPORIN was therapeutically significantly less effective in
vivo against HSB-2 cells xenografted into NOD/SCID mice in
comparison to the therapeutic effects obtained in SCID mice. We
observed in one experiment that 70% of NOD/SCID-HSB-2 mice
treated with IT developed signs and symptoms of leukaemia cell
growth at virtually the same rate as PBS sham-treated controls, and
achieved ultimately only a 30% disease-free survival rate. This
compares with an 80% survival rate in equivalent SCID mice
treated with the same IT. This was even more pronounced in a
second experiment where HB2-SAPORIN was almost completely
ineffective, giving only a very modest increase in the time taken to
develop symptoms compared with PBS sham-treated controls and
with all animals in this treatment group eventually showing demon-
strable leukaemia cell growth. The HB2-F(ab)2-SAPORIN IT.
which is incapable of recruiting NK cells due to its lack of an Fc
domain, performed in a near identical fashion to HB2-SAPORIN.
These findings in NOD/SCID mice are remarkably similar to the
observed outcome when standard SCID mice bearing HSB-2
leukaemia are depleted of their NK cells with anti-asialo GM1 anti-
body and then treated with HB2-SAPORIN IT (Flavell et al, 1998).
Here the therapeutic effect of HB2-SAPORIN was significantly
reduced in NK cell-depleted animals in comparison to NK cell-
intact animals. Just as in NOD/SCID-HSB-2 mice treated with the
IT HB2-SAPORIN in the present study, the majority of SCID-
HSB-2 mice depleted of their NK cells with anti-asialo GM1 anti-
body also died at a similar rate as sham-treated controls (Flavell et
al, 1998). This allowed us to draw the conclusion that ADCC medi-
ated by NK or NK-like cells contributed additively to the overall
therapeutic effect of HB2-SAPORIN in the SCID-HSB-2 model.
The present study would seem to provide further support for this
hypothesis, that is to say that it is the absence of effective in vivo
ADCC in NOD/SCID-HSB-2 mice that reduces the therapeutic
effect of the IT HB2-SAPORIN. The cautionary lesson to be
learned here is simply that the non-adaptive immune status of
immunodeprived mice can significantly influence the therapeutic
evaluation of antibody-based drugs like HB2-SAPORIN and give a
misleading overestimate of their intrinsic anti-tumour potency. On
the positive side such in vivo animal models also provide a means
of delineating and defining contributory additivities between mech-
anistically different antibody-mediated anti-tumour activities and
provide us with valuable insights that may eventually assist us in
the development of multi-modal targeted approaches for the treat-
ment of human malignancies. 
ACKNOWLEDGEMENTS 
This work was supported by the children’s leukaemia research
charity Leukaemia Busters. We would like to thank Dr Finbarr
Cotter for generously providing the NOD/SCID mice breeding
pairs and the staff of the Biomedical Research Facility (University
of Southampton) for their expert technical assistance. 
REFERENCES 
Adams RA, Pothier L, Flowers A, Lazarus H, Farber S and Foley GE (1970) The
question of stemlines in human acute leukemia. Comparison of cells isolated in
vitro and in vivo from a patient with acute lymphoblastic leukemia.
Experimental Cell Research 62: 5–10 
Baxter AG and Cooke A (1993) Complement lytic activity has no role in the
pathogenesis of autoimmune diabetes in NOD mice. Diabetes 42: 
1574–1578 
Bhatia M, Wang JCY, Kapp U, Bonnet D and Dick JE (1997) Purification of
primitive human hematopoietic cells capable of repopulating immune-deficient
mice. PNAS 94: 5320–5325 
Bosma GC, Custer RP and Bosma MJ (1983) A severe combined immunodeficiency
mutation in the mouse. Nature 301: 527–530 
Cesano A, O’Connor R, Lange B, Finan J, Rovera G and Santoli D (1991) Homing
and progression patterns of childhood acute lymphoblastic leukaemias in
severe combined immunodeficient mice. Blood 77: 2463–2474 
Christianson SW, Shultz LD and Leiter EH (1993) Adoptive transfer of diabetes into
immunodeficient NOD-scid/scid mice. Relative contributions of CD4+ and
CD8+ T-cells from diabetic versus prediabetic NOD. NON-Thy-1a donors.
Diabetes 42: 44–55 
Cikes M, Friberg S and Klein G (1973) Progressive loss of H-2 antigens with
concomitant increase of cell-curface antigen(s) determined by Moloney
Leukemia Virus in cultured murine lymphomas. Journal of National Cancer
Instute 50: 347–362 
Custer RP, Bosma GC and Bosma MJ (1985) Severe combined immunodeficiency
(SCID) in the mouse. Pathology, reconstitution, neoplasms. Am J Pathol 120:
464–477 
Dick JE (1996) Normal and leukemic human stem cells assayed in SCID mice.
Semin Immunol, 8: 197–206 
Dorshkind K, Keller GM, Phillips RA, Miller RG, Bosma GC, O’Toole M and
Bosma MJ (1984) Functional status of cells from lymphoid and myeloid tissues
in mice with severe combined immunodeficiency disease. J Immunol 132:
1804–1808 
Dorshkind K, Pollack SB, Bosma MJ and Phillips RA (1985) Natural killer cells are
present in mice with severe combined immunodeficiency. Journal of
Immunology 134: 3798–3801 
Flavell DJ (1996) Modelling human leukaemia and lymphoma in severe combined
immunodeficient (Scid) mice: practical applications. Haematological Oncology
14: 67–82 
Flavell DJ, Boehm DA, Noss A and Flavell SU (1997) Comparison of the potency
and therapeutic efficacy of the anti-CD7 immunotoxin HB2-Saporin
constructed with one or two saporin moieties per immunotoxin molecule.
British Journal of Cancer 75: 1035–1043 
Flavell DJ, Warnes S, Noss A and Flavell SU (1998) Host-mediated antibody
dependent cellular cytotoxicity (ADCC) contributes to the in vivo therapeutic
efficacy of an anti-CD7-saporin immunotoxin in a SCID mouse model of
human T-ALL. Cancer Research 58: 5787–5794 
Kamel-Reid S, Letarte M, Sirard C, Doedens M, Grunberger T, Fulop G, Freedman
MH, Phillips RA and Dick JE (1989) A model of human acute lymphoblastic
leukemia in immune-deficient SCID mice. Science 246: 1597–1600 
Kamel-Reid S, Letarte M, Doedens M, Greaves A, Murdoch B, Grunberger T,
Lapidot T, Thorner P, Freedman MH, Phillips RA and Dick JE (1991) Bone
marrow from children in relapse with pre-B acute lymphoblastic leukaemia
proliferates and disseminates rapidly in SCID mice. Blood 78: 
2973–2981 
Kataoka S, Satoh J, Fujiya H, Toyota T, Suzuki R, Itoh K and Kumagai K (1983)
Immunologic aspects of the nonobese diabetic (NOD) mouse. Abnormalities of
cellular immunity. Diabetes 32: 247–253 
Kollmann TR, Kim A, Zhuang X, Hachamovitch M and Goldstein H (1994)
Reconstitution of SCID mice with human lymphoid and myeloid cells after
transplantation with human fetal bone marrow without the requirement for
exogenous human cytokines. PNAS 91: 8032–8036 
Kotloff DB, Bosma MJ and Ruetsch NR (1993) Scid mouse pre-B cells with
intracellular µ chains: analysis of recombinase activity and IgH gene
rearrangements. Int Immunol 5: 383–391 
Lapidot T, Pflumio F, Doedens M, Murdoch B, Williams DE and Dick JE (1992)
Cytokine stimulation of multilineage hematopoiesis from immature human
cells engrafted in SCID mice. Science 255: 1137–1141 
1760 DJ Flavell et al
British Journal of Cancer (2000) 83(12), 1755–1761 © 2000 Cancer Research CampaignMorland BJ, Barley J, Boehm D, Flavell SU, Ghaleb N, Kohler JA, Okayama K,
Wilkins B and Flavell DJ (1994) Effectiveness of HB2(anti-CD7)-saporin
immunotoxin in an in vivo model of human T-cell leukaemia developed in severe
combined immunodeficient mice. British Journal of Cancer 69: 279–285 
Pilarski LM, Hipperson G, Seeberger K, Pruski E, Coupland RW and Belch AR
(2000) Myeloma progenitors in the blood of patients with aggressive or minimal
disease: engraftment and self-renewal of primary human myeloma in the bone
marrow of NOD SCID mice. Blood 95: 1056–1065 
Prochazka M, Gaskins HR, Shultz LD and Leiter EH (1992) The non-obese diabetic
scid mouse:model for spontaneous thymomagenesis associated with
immunodeficiency. PNAS 89: 3290–3294 
Serreze DV and Leiter EH (1988) Defective activation of T suppressor cell function
in nonobese diabetic mice. Potential relation to cytokine deficiencies. 
J Immunol 140: 3801–3807 
Serreze DV, Gaskins HR and Leiter EH (1993) Defects in the differentiation and
function of antigen presenting cells in NOD/Lt mice. J Immunol 150: 2534–2543 
Shpitz B, Fernandes BJ, Mullen JBM, Roder JC and Gallinger S (1994) Improved
engraftment of human tumours in SCID mice pretreated with radiation and
anti-asialo GMI. Anticancer Research 14: 1927–1934 
Shultz L, Schweitzer PA, Christianson SW, Gott B, Schweitzer IB, Tennent B,
McKenna S, Mobraaten L, Rajan TV, Greiner DL and Leiter EH (1995)
Multiple defects in innate and adaptive immunologic function in NOD/LtSz-
scid mice. The Journal of Immunology 154: 180–191 
Thorpe PE, Brown ANF, Jr, JAGB, Foxwell BMJ and Stirpe F (1985) An
immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-
inactivating protein from Saponaria officinalis: potent antitumor effects in vitro
and in vivo. Journal of National Cancer Institute 75: 151–159 
Wang JCY, Lapidot T, Cashman JD, Sirard C, Doedens M, Laraya P, 
Addy L, Minden M, Keating A, Eaves AC, Eaves CJ and Dick JE
(1995) Engraftment of primitive normal and leukemic hematopoetic cells 
from chronic phase CML patients in immunodeficient mice. Blood 86: 
601a 
Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J,
Newell D, Raymond R, Stables J, Stephens T and Wallace J (1998) United
Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines
for the welfare of animals in experimental neoplasia (second edition). Br J
Cancer 77: 1–10 
Yu J, Dialynas DP, Shao LE, Lee MJ, Gold DP and Yu AL (1999) Fetal cord 
blood facilitates engraftment of primary childhood T-cell acute 
lymphoblastic leukaemia in immunodeficient mice and enhances leukaemia
colony formation in vitro. Proc Am Assoc Cancer Res 40: 660 
(abstract #4352) 
Immunotherapy in immunodeprived mice 1761
British Journal of Cancer (2000) 83(12), 1755–1761 © 2000 Cancer Research Campaign